Multiple myeloma cell survival relies on high activity of protein kinase CK2

Blood

Volumn 108, Issue 5, 2006, Pages 1698-1707

  Piazza, Francesco A ^b   Ruzzene, Maria ^b   Gurrieri, Carmela ^b   Montini, Barbara ^b   Bonanni, Luca ^b   Chioetto, Gino ^b   Di Maira, Giovanni ^b   Barbon, Francesca ^b   Cabrelle, Anna ^b   Zambello, Renato ^b   Adami, Fausto ^b   Trentin, Livio ^b   Pinna, Lorenzo A ^b   Semenzato, Gianpietro ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CASEIN KINASE II; CASPASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MELPHALAN; PROTEIN INHIBITOR; PROTEIN P50; SOMATOMEDIN; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CELL VIABILITY; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; GENE CONTROL; GENETIC TRANSCRIPTION; HUMAN; IN VITRO STUDY; LYMPHOCYTE; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PURIFICATION; RNA INTERFERENCE;

EID: 33748163052     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-11-013672     Document Type: Article

References (61)

1. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer. 2002;2:175-187.
2. Matsui W, Huff CA, Wang Q, et al. Characterization of clonogenic multiple myeloma cells. Blood. 2004;103:2332-2336.
3. Mitsiades CS, Mitsiades N, Munshi NC, Anderson KC. Focus on multiple myeloma. Cancer Cell. 2004;6:439-444.
4. Richardson P, Hideshima T, Anderson KC. An update of novel therapeutic approaches for multiple myeloma. Curr Treat Options Oncol. 2004;5:227-238.
5. Yang HH, Ma MH, Vescio RA, Berenson JR. Overcoming drug resistance in multiple myeloma: the emergence of therapeutic approaches to induce apoptosis. J Clin Oncol. 2003;21:4239-4247.
6. Li PF, Li J, Muller EC, Otto A, Dietz R, von Harsdorf R. Phosphorylation by protein kinase CK2: a signaling switch for the caspase-inhibiting protein ARC. Mol Cell. 2002;10:247-258.
7. Ruzzene M, Penzo D, Pinna LA. Protein kinase CK2 inhibitor 4,5,6,7-tetrabromobenzotriazole (TBB) induces apoptosis and caspase-dependent degradation of haematopoietic lineage cell-specific protein 1 (HS1) in Jurkat cells. Biochem J. 2002;364:41-47.
8. Ahmed K, Gerber DA, Cochet C. Joining the cell survival squad: an emerging role for protein kinase CK2. Trends Cell Biol. 2002;12:226-230.
9. Tawfic S, Yu S, Wang H, Faust R, Davis A, Ahmed K. Protein kinase CK2 signal in neoplasia. Histol Histopathol. 2001;16:573-582.
10. Pinna LA. Protein kinase CK2: a challenge to canons. J Cell Sci. 2002;115:3873-3878.
11. Litchfield DW. Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem J. 2003;369:1-15.
12. Faust RA, Niehans G, Gapany M, et al. Subcellular immunolocalization of protein kinase CK2 in normal and carcinoma cells. Int J Biochem Cell Biol. 1999;31:941-949.
13. Barroga CF, Stevenson JK, Schwarz EM, Verma IM. Constitutive phosphorylation of I κ B α by casein kinase II. Proc Natl Acad Sci U S A. 1995;92:7637-7641.
14. Janosch P, Schellerer M, Seitz T, et al. Characterization of IκB kinases: IκB-α is not phosphorylated by Raf-1 or protein kinase C isozymes, but is a casein kinase II substrate. J Biol Chem. 1996;271:13868- 13874.
15. Taylor JA, Bren GD, Pennington KN, Trushin SA, Asin S, Paya CV. Serine 32 and serine 36 of IκBα are directly phosphorylated by protein kinase CKII in vitro. J Mol Biol. 1999;290:839-850.
16. Wang D, Westerheide SD, Hanson JL, Baldwin ASJ. Tumor necrosis factor α-induced phosphorylation of RelA/p65 on Ser529 is controlled by casein kinase II. J Biol Chem. 2000;275:32592-32597.
17. Bird TA, Schooley K, Dower SK, Hagen H, Virca GD. Activation of nuclear transcription factor NF-κB by interleukin-1 is accompanied by casein kinase II-mediated phosphorylation of the p65 subunit. J Biol Chem. 1997;272:32606-32612.
18. Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson KC. The role of tumor necrosis factor α in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene. 2001;20:4519-4527.
19. Mitsiades CS, Mitsiades N, Poulaki V, et al. Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene. 2002;21:5673-5683.
20. Lust JA, Donovan KA. The role of interleukin-1 β in the pathogenesis of multiple myeloma. Hematol Oncol Clin North Am. 1999;6:1117-1125.
21. Dessauge F, Hilaly S, Baumgartner M, Blumen B, Werling D, Langsley G. c-Myc activation by Theileria parasites promotes survival of infected B-lymphocytes. Oncogene. 2005;24:1075-1083.
22. Hoffman B, Amanullah A, Shafarenko M, Liebermann DA. The proto-oncogene c-myc in hematopoietic development and leukemogenesis. Oncogene. 2002;21:3414-3421.
23. Channavajhala P, Seldin DC. Functional interaction of protein kinase CK2 and c-Myc in lymphomagenesis. Oncogene. 2002;21:5280-5288.
24. Lee H, Arsura M, Wu M, Duyao M, Buckler AJ, Sonenshein GE. Role of Rel-related factors in control of c-myc gene transcription in receptor-mediated apoptosis of the murine B cell WEHI 231 line. J Exp Med. 1995;181:1169-1177.
25. Grumont RJ, Strasser A, Gerondakis S. B cell growth is controlled by phosphatidylinosotol 3-kinase-dependent induction of Rel/NF-κB regulated c-myc transcription. Mol Cell. 2002;10:1283-1294.
26. Filhol-Cochet O, Loue-Mackenbach P, Cochet C, Chambaz EM. Casein kinase 2 and the cell response to growth factors. Cell Mol Biol Res. 1994;40:529-537.
27. Miyata Y, Nishida E. CK2 controls multiple protein kinases by phosphorylating a kinase-targeting molecular chaperone, Cdc37. Mol Cell Biol. 2004;24:4065-4074.
28. Trentin L, Zambello R, Agostini C, et al. Mechanisms accounting for the defective natural killer activity in patients with hairy cell leukemia. Blood. 1990;75:1525-1530.
29. Tarte K, De Vos J, Thykjaer T, et al. Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasma-blasts. Blood. 2002;100:1113-1122.
30. Trentin L, Perin A, Siviero M, et al. B7 costimulatory molecules from malignant cells in patients with B-cell chronic lymphoproliferative disorders trigger T-cell proliferation. Cancer. 2000;89:1259-1268.
31. Szyszka R, Grankowski N, Felczak K, Shugar D. Halogenated benzimidazoles and benzotriazoles as selective inhibitors of protein kinases CK I and CK II from Saccharomyces cerevisiae and other sources. Biochem Biophys Res Commun. 1995;208:418-424.
32. Sarno S, de Moliner E, Ruzzene M, et al. Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]-acetic acid (IQA). Biochem J. 2003;374:639-646.
33. Pagano MA, Andrzejewska M, Ruzzene M, et al. Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004;47:6239-6247.
34. Sarno S, Reddy H, Meggio F, et al. Selectivity of 4,5,6,7- tetrabromobenzotriazole, an ATP site-directed inhibitor of protein kinase CK2 ('casein kinase-2'). FEBS Lett. 2001;496:44-48.
35. Pagano MA, Meggio F, Ruzzene M, Andrzejewska M, Kazimierczuk Z, Pinna LA. 2-Dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole: a novel powerful and selective inhibitor of protein kinase CK2. Biochem Biophys Res Commun. 2004;321:1040-1044.
36. Ruzzene M, Brunati AM, Sarno S, Donella-Deana A, Pinna LA. Hematopoietic lineage cell specific protein 1 associates with and down-regulates protein kinase CK2. FEBS Lett. 1999;461:32-36.
37. Saggioro D, Barp S, Chieco-Bianchi L. Block of a mitochondrial-mediated apoptotic pathway in Tax-expressing murine fibroblasts. Exp Cell Res. 2001;269:245-255.
38. Sarno S, Vaglio P, Meggio F, Issinger OG, Pinna LA. Protein kinase CK2 mutants defective in substrate recognition: purification and kinetic analysis. J Biol Chem. 1996;271:10595-10601.
39. de Lange P, Segeren CM, Koper JW, et al. Expression in hematological malignancies of a glucocorticoid receptor splice variant that augments glucocorticoid receptor-mediated effects in transfected cells. Cancer Res. 2001;61:3937-3941.
40. Marin O, Meggio F, Sarno S, Andretta M, Pinna LA. Phosphorylation of synthetic fragments of inhibitor-2 of protein phosphatase-1 by casein kinase-1 and -2: evidence that phosphorylated residues are not strictly required for efficient targeting by casein kinase-1. Eur J Biochem. 1994;223:647-653.
41. Sarno S, Salvi M, Battistutta R, Zanotti G, Pinna LA. Features and potentials of ATP-site directed CK2 inhibitors. Biochim Biophys Acta. 2005;1754:263-270.
42. Nilsson K, Jernberg H, Pettersson M. IL-6 as a growth factor for human multiple myeloma cells - a short overview. Curr Top Microbiol Immunol. 1990;166:3-12.
43. Potter M. Neoplastic development in plasma cells. Immunol Rev. 2003;194:177-195.
44. Klein B, Zhang XG, Lu ZY, Bataille R. Interleukin-6 in human multiple myeloma. Blood. 1995;85:863-872.
45. Filhol O, Nueda A, Martel V, et al. Live-cell fluorescence imaging reveals the dynamics of protein kinase CK2 individual subunits. Mol Cell Biol. 2003;23:975-987.
46. Padmanabha R, Chen-Wu JL, Hanna DE, Glover CV. Isolation, sequencing, and disruption of the yeast CKA2 gene: casein kinase II is essential for viability in Saccharomyces cerevisiae. Mol Cell Biol. 1990;10:4089-4099.
47. Xu X, Toselli PA, Russell LD, Seldin DC. Globozoospermia in mice lacking the casein kinase II α′ catalytic subunit. Nat Genet. 1999;23:118-121.
48. Krippner-Heidenreich A, Talanian RV, Sekul R, et al. Targeting of the transcription factor Max during apoptosis: phosphorylation-regulated cleavage by caspase-5 at an unusual glutamic acid residue in position P1. Biochem J. 2001;358:705-715.
49. Desagher S, Osen-Sand A, Montessuit S, et al. Phosphorylation of bid by casein kinases I and II regulates its cleavage by caspase 8. Mol Cell. 2001;8:601-611.
50. Guerra B, Boldyreff B, Issinger OG. FAS-associated factor 1 interacts with protein kinase CK2 in vivo upon apoptosis induction. Int J Oncol. 2001;19:1117-1126.
51. Izeradjene K, Douglas L, Delaney A, Houghton JA. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells. Clin Cancer Res. 2004;10:6650-6660.
52. Torres J, Rodriguez J, Myers MP, et al. Phosphorylation-regulated cleavage of the tumor suppressor PTEN by caspase-3: implications for the control of protein stability and PTEN-protein interactions. J Biol Chem. 2003;278:30652-30660.
53. Izeradjene K, Douglas L, Delaney A, Houghton JA. Casein kinase II (CK2) enhances death-inducing signaling complex (DISC) activity in TRAIL-induced apoptosis in human colon carcinoma cell lines. Oncogene. 2005;24:2050-2058.
54. Wang G, Ahmad KA, Ahmed K. Role of protein kinase CK2 in the regulation of tumor necrosis factor-related apoptosis inducing ligand-induced apoptosis in prostate cancer cells. Cancer Res. 2006;66:2242-2249.
55. Shin S, Lee Y, Kim W, Ko H, Choi H, Kim K. Caspase-2 primes cancer cells for TRAIL-mediated apoptosis by processing procaspase-8. EMBO J. 2005;24:4209-4210.
56. Loizou JI, El-Khamisy SF, Zlatanou A, et al. The protein kinase CK2 facilitates repair of chromosomal DNA single-strand breaks. Cell. 2004;117:17-28.
57. + cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood. 2004;103:3175-3184.
58. Podar K, Tai YT, Davies FE, et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood. 2001;98:428-435.
59. Chesi M, Brents LA, Ely SA, et al. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood. 2001;97:729-736.
60. Shen J, Channavajhala P, Seldin DC, Sonenshein GE. Phosphorylation by the protein kinase CK2 promotes calpain-mediated degradation of IκBα. J Immunol. 2001;167:4919-4925.
61. Kim YS, Lee JY, Son MY, Park W, Bae YS. Phosphorylation of threonine 10 on CKBBP1/SAG/ROC2/Rbx2 by protein kinase CKII promotes the degradation of IκBα and p27Kip1. J Biol Chem. 2003;278:28462-28469.